Posted by Michael Wonder on 26 Aug 2021
AbbVie receives a positive reimbursement recommendation from the Canadian Agencies for Drugs and Technology in Health (CADTH) pan-Canadian Oncology Drug Review Expert Review Committee (pERC) for Venclexta (venetoclax) in combination with azacitidine for acute myeloid leukaemia patients
26 August 2021 - pERC recommends reimbursement of Venclexta (venetoclax) in combination with azacitidine for the treatment of newly diagnosed acute myeloid leukaemia who are ineligible for intensive induction chemotherapy.
AbbVie announced today that the CADTH pCODR Expert Review Committee (pERC) recommends that Venclexta (venetoclax) in combination with azacitidine should be reimbursed for the treatment of patients with newly diagnosed acute myeloid leukaemia who are 75 years or older, or who have co-morbidities that preclude use of intensive induction chemotherapy, only if the conditions listed are met.
